ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

クリオキノール

Clioquinol

HCID 2788
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
130-26-7
標準SMILES
Oc1c(I)cc(Cl)c2cccnc12
InChIKey
QCDFBFJGMNKBDO-UHFFFAOYSA-N
分子式
C9H5ClINO
平均分子量
305.5 g/mol
単同位体質量
304.91044

概要

Iodochlorohydroxyquinoline is a cream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179 °C. Used as a topical anti-infective.

名称と識別子

優先名称
Clioquinol
IUPAC
5-chloro-7-iodoquinolin-8-ol
現地名
クリオキノール
英語名
Clioquinol
分子式
C9H5ClINO
分子量
305.5

名称と別名

clioquinol130-26-75-Chloro-7-iodoquinolin-8-olIodochlorhydroxyquinChloroiodoquinVioform5-Chloro-8-hydroxy-7-iodoquinolineChloroiodoquineCliquinol5-Chloro-7-iodo-8-quinolinolIodochloroxyquinolineIodoenterol
名称をさらに表示
5-クロロ-8-ヒドロキシ-7-ヨードキノリンエントロキンヨードエンテロールキナンビシドキノホルムアモエノールエスゼシジン5-クロロ-7-ヨード-8-キノリノールロメチンアメビルブドホルムバルキノール5-クロロ-7-ヨードキノリン-8-オールアルクロキンバクトールエンテロ-セプトールヒ-エンテロールヨードクロロヒドロキシキンエンテロキノールエンテロ-ビオホルムIODOCHLOROHYDROXYQUINOLINENystaform5-Chlor-7-jod-8-hydroxy-chinolinIODOCHLOROHYDROXYQUINOLINE (CLIOQUINOL)AmebilBactolhysone
5-Chloro-7-iodo-8-hydroxyquinoline7-Iodo-5-chloroxineIodochloroquineAlchloquinBarquinolChlorojodochinEczecidinEnterozol

データベース識別子

CAS
130-26-7
PubChem CID
2788
DTXSID
DTXSID7022837
ChEMBL
CHEMBL497
ChEBI
CHEBI:74460
UNII
7BHQ856EJ5
EC Number
204-984-4
Nikkaji
J5.432A

物性

構造計算による物性補完中

XLogP
3.5
極性表面積
33.1 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
0
重原子数
13
形式電荷
0
複雑度
192

実験および物理化学的性質

Chemical ClassesOther Uses -> Pharmaceuticals
Drugs · 2 件

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Odor · 2 件

Practically odorless

Slight characteristic odor

Color/Form · 3 件

Brownish-yellow, bulky powder

Yellow brown needles from alcohol, acetic acid.

A voluminous, spongy, yellowish to white brownish powder

Solubility · 4 件

less than 1 mg/mL at 68 °F (NTP, 1992)

One part dissolves in 43 parts of boiling alcohol, 128 parts chloroform, 17 parts of boiling ethyl acetate, 170 parts of cold acetic acid, 13 parts of boiling acetic acid. Almost insol in water, and alcohol, ether.

Practically insol water and in alcohol

0.8 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal DrugsFDA approved animal drugs -> Active ingredient
DecompositionWhen heated to decomposition it emits very toxic fumes of /hydrogen chloride, hydrogen iodide and nitrogen oxides/.

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (41.5%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 147 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

Chemical: 8-Quinolinol, 5-chloro-7-iodo-

REACH registered substance: Clioquinol (EC: 204-984-4)

Other Safety InformationIMAP assessments - 8-Quinolinol, 5-chloro-7-iodo-: Environment tier I assessment
Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1 件

SYMPTOMS: Symptoms of exposure to this compound include changes in central nervous system electrical function and optic nerve damage. Other symptoms include abdominal discomfort, diarrhea, paresthesias in the legs (possibly progressing to paraplegia), loss of visual acuity (sometimes leading to irreversible blindness), characteristic green pigmentation of the tongue, feces and urine, sensory disturbances and subacute myelo-optic neuropathy. Irritation of the skin, eyes, mucous membranes and upper respiratory tract may occur.

Hazards Summary · 1 件

Allergic contact dermatitis reported in patients using this antibiotic topically; [Marks, p. 123-4] An epidemic of subacute myelo-optico-neuropathy occurred in Japan from 1956 until 1970. Approximately 10,000 cases were reported with visual impairment, lower extremity paresthesias and weakness, and other symptoms. Symptoms resolved after the oral medication was discontinued. Neurotoxicity developed in patients who received total doses greater that 750 mg/day for four weeks. [HSDB]

化学と産業

薬理情報

ATC Code · 6 件

S - Sensory organs

D - Dermatologicals

P - Antiparasitic products, insecticides and repellents

D - Dermatologicals

G - Genito urinary system and sex hormones

QS - Sensory organs

Pharmacodynamics · 1 件

Clioquinol is a broad-spectrum antibacterial with antifungal properties. Application of clioquinol to extensive or eroded areas of the skin may lead to increased protein-bound iodine (PBI) levels within 1 week. In addition, elevated PBI levels may occur when relatively small areas of the skin are treated with clioquinol for more than 1 week.

Mechanism of ActionClioquinol is bacteriostatic, however, the precise mechanism of its action is unknown.
Biological Half-Life11-14 hr
Metabolism/MetabolitesClioquinol has known human metabolites that include Clioquinol O-glucuronide.
FDA Pharmacological Classification · 6 件

7BHQ856EJ5

CLIOQUINOL

Established Pharmacologic Class [EPC] - Standardized Chemical Allergen

Physiologic Effects [PE] - Increased Histamine Release

Physiologic Effects [PE] - Cell-mediated Immunity

Chemical Structure [CS] - Allergens

Absorption, Distribution and Excretion · 3 件

Topical absorption is rapid and extensive, especially when the skin is covered with an occlusive dressing or if the medication is applied to extensive or eroded areas of the skin. Clioquinol is absorbed through the skin in sufficient amounts to affect thyroid function tests.

Clioquinol is absorbed systemically following topical application to the skin. In 2 studies in which clioquinol combined with a corticosteroid was applied topically to the skin as a cream or ointment, it was estimated that about 2-3% of the dose was absorbed systemically. However, in another study in which the drug was applied alone to the skin as a 3% cream and covered with an occlusive wrap for 12 hr, it was estimated that about 40% of the dose was absorbed percutaneously during this period.

関連反応

12 件
反応記録を作成
HRID 382880 の反応式
HRID 382880反応物として
HRID 382881 の反応式
HRID 382881反応物として
HRID 623403 の反応式
HRID 623403反応物として
HRID 800732 の反応式
HRID 800732反応物として
HRID 828411 の反応式
HRID 828411反応物として
HRID 872226 の反応式
HRID 872226反応物として
HRID 1069520 の反応式
HRID 1069520反応物として
HRID 1069521 の反応式
HRID 1069521反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Melting Point · 2 件

352 to 354 °F (NTP, 1992)

178-179 °C

Physical DescriptionIodochlorohydroxyquinoline is a cream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179 °C. Used as a topical anti-infective.
Stability/Shelf LifeClioquinol darkens on exposure to light.
Collision Cross Section138.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
175 · 175-183 °C
沸点
350.4 · 350.4±37.0 °C(Predicted)
比重(密度)
1.8959 · 1.8959 (estimate)
蒸気圧
0 Pa · 0Pa at 25℃
貯蔵温度
2 · 2-8°C
溶解性
DMSO (>25 mg/ml)、沸騰アルコール ((1:43))、メタノール、クロロホルム ((1:120)) に可溶。
酸解離定数(Pka)
8.12 · pKa 8.12(50%aqEtOH t=35.0±0.1 I=0.00 N2atmosphere)(Approximate)
外見
個体
色
ライトベージュからベージュ
水溶解度
0.1 g/100 · <0.1 g/100 mL で 20 ºC
Merck
14 · 14,5031
BRN
153637 · 153637
主な用途
法医学と毒物学医薬品(低分子化合物)
InChI
1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
InChIKey
QCDFBFJGMNKBDO-UHFFFAOYSA-N
SMILES
Oc1c(I)cc(Cl)c2cccnc12
LogP
1.523 at · 1.523 at 24℃
CAS データベース
130 · 130-26-7(CAS DataBase Reference)
NISTの化学物質情報
5 · 5-Chloro-7-iodo-8-quinolinol(130-26-7)
EPAの化学物質情報
Clioquinol (130-26-7)

化学的性質

化学的特性Almost white, light yellow, brownish-yellow or yellowish-grey powder.

FDA Requirements · 2 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl clioquinol hydrocortisone and clioquinol nystatin, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Clioquinol hydrocortisone and clioquinol nystatin/

Reactive GroupAmines, Phosphines, and Pyridines
Reactivity ProfileIODOCHLOROHYDROXYQUINOLINE is incompatible with strong oxidizing agents, strong acids, acid chlorides and acid anhydrides (NTP, 1992). Darkens on exposure to light.
Air and Water ReactionsInsoluble in water.
Hazard Classes and CategoriesAcute Tox. 3 (41.5%)

安全と保護具

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Storage ConditionsClioquinol cream should be stored in collapsible tubes or in tight, light-resistant containers. Topical preparations containing clioquinol should be stored at a temperature less than 30 °C; freezing should be avoided.
Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: If a spill of this chemical occurs, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with acetone and transfer the dampened material to a suitable container. Use absorbent paper dampened with acetone to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with acetone followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Personal Protective Equipment (PPE) · 1 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

毒性情報

Adverse EffectsSkin Sensitizer - An agent that can induce an allergic reaction in the skin.
Human Toxicity Excerpts · 5 件

Beginning in 1956, an epidemic of a new GI neurologic syndrome, subacute myelo-optico-neuropathy, occurred in Japan. When it was publicly announced on August 7, 1970, approximately 10,000 cases had already been reported. Its etiologic agent was identified as iodochlorhydroxyquin. By September 8, 1970, all halogenated hydroxyquinolines were removed from the market in Japan. Since then, the epidemic has not recurred.

Criteria for the diagnosis of subacute myelo-optico-neuropathy. Cardiac Signs: Abdominal symptoms (abdominal pain, diarrhea, etc.) before the onset of neurological symptoms. Acute or subacute onset of bilateral ascending paresthesia and dysesthesia of the lower extremities. Other Major Signs: Impairment of deep sensation and weakness in the lower limbs, with or without pyramidal signs. Less commonly, sensorimotor disturbances in the upper limbs. Occasionally, one or more of the following: a. Bilateral impairment of vision. b. Disturbances of consciousness, convulsions, psychic symptoms, and other cerebral symptoms. c. Greenish discoloration of the tongue and feces. d. Sphincter disturbances. Protracted course with occasional relapses. No significant laboratory findings in blood and cerebrospinal fluid. Rare occurrence in children.

... There have been many similar cases of subacute myelo-optico-neuropathy scattered in various parts of the world affecting adults, with convincing histories relating clioquinol to disturbances of vision, with varying deg of spinal cord involvement. Visual disturbances have ranged from impairment of discrimination of colors to blindness from optic atrophy, with moderate involvement in the form of central scotomas with symmetrically reduced visual acuity. Clinical ophthalmoscopic abnormality appears to be limited to pallor of the disc in eyes with optic atrophy. In a number of cases there has been improvement of vision during several months after administration of clioquinol was discontinued. No treatment has been effective other than stopping administration of clioquinol.

Some of the earliest suspicions of toxicity affecting vision were in relation to children who were being treated for acrodermatitis enteropathica for long periods with large doses when their vision was found to be much impaired, and optic atrophy was diagnosed. Some children had difficulty in walking as well as poor vision. An investigating committee reported in 1974 knowledge of more than a dozen children with optic neuropathy from clioquinol. Less than half had symptoms of peripheral neuropathy.

A neurotoxicity dose response curve for iodochlorhydroxyquin can be constructed as follows: 750 mg/day for 4 wk or less little risk of toxic reactions. 750-1500 mg/day for less than 2 wk 1% have neurologic symptoms. 750-1,500 mg/day for over 2 wk 35% develop symptoms. 1800 mg/day for 5 days one patient developed symptoms. At higher doses onset of toxic reactions may begin within 24 hr after beginning therapy. The clinical symptoms associated with ingestion of halogenated hydroxyquinolines are primarily those of peripheral neuropathy or myelopathy, with occasional cerebral manifestations. Symptoms range from minimal dysesthesia to death and include optic atrophy.

Non-Human Toxicity Excerpts · 1 件

In dogs, clioquinol caused decrease of visual acuity, with vacuolation and loss of axons in the optic tract. There seems to be agreement that peripheral nerves are not primarily affected, but that long tracts in the spinal cord show degeneration, and that the relatively short axons of the optic nerves are especially vulnerable. The seemingly unique distribution has been termed central distal axonopathy. Demyelination follows axon degeneration.

Populations at Special Risk... Use in those younger than 2 years of age is contraindicated.
Antidote and Emergency Treatment · 1 件

Emesis induction is indicated after adult ingestion of 1,500 to 1,800 mg of clioquinol if there is no coma, convulsions, or loss of gag reflex. Otherwise, gastric lavage with tracheal protection, activated charcoal, and cathartics. There are no data on the use of forced diuresis, hemodialysis, peritoneal dialysis, hemoperfusion, or exchange transfusion in the treatment of halogenated 8-hydroxyquinoline poisonings. There are no antidotes.

法規制情報

FDA Requirements · 2 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl clioquinol hydrocortisone and clioquinol nystatin, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Clioquinol hydrocortisone and clioquinol nystatin/

安全データ

wgk
3
tsca
TSCA listed
rtecs
VC5075000
ridadr
UN 2811 6.1/PG 3
毒性
LD50 orally in cats: 400 mg/kg (Davis)
hs_code
2933492250
risk_code
25
hazard_code
T
safety_code
36/37/39-45
hazard_class
6.1(b)
packing_group
III
Hazard Classifications
Acute Tox. 3 OralEye Irrit. 2Skin Irrit. 2Skin Sens. 1
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
有毒物質データの
130-26-7(Hazardous Substances Data)

Patients with widespread dermatitis were treated with 15-20 g of 3% clioquinol ointment to 40% of the body area twice daily. The serum concentration increased to 0.8-1.2 ug/ml within 4 hr of application. In one patient, 15-20 mg was excreted in the urine daily mainly in the form of conjugated metabolites. This skin treatment resulted in a urinary excretion somewhat less than is obtained after a daily oral dose of 25 mg (one tablet) of clioquinol. Thus, 3-4% of the applied clioquinol was absorbed. 25% was excreted in the urine.

用途と製造

Uses · 4 件

Used as a medicinal cream, ointment, or powder; [HSDB]

MEDICATION (VET)

MEDICATION

Use (kg; approx.) in Germany (2009): >250

Formulations/Preparations · 4 件

Topical Cream 3%, Iodochlorhydroxyquin Cream, CMC.

Topical Cream, 3% with Hydrocortisone 0.5%, Ala-Quin, Del-Ray; Vioform -Hydrocortisone Mild, Ciba; 3% with Hydrocortisone 1%, Corque, Geneva; Cortin, C & M Pharmacal; Hysone, Mallard; Vioform -Hydrocortisone; Ciba 3% with Hydrocortisone 1% and Pramoxine Hydrochloride 1% 1 + 1-F, Dunhall Lotion, 0.75% with Hydrocortisone 0.25%, UAD Lotion (with parabens and propylene glycol), UAD Laboratories Ointment, 3% with Hydrocortisone 1%, Vioform-Hydrocortisone, Ciba.

Cream and ointment, 3%

Clipquinol is available in the United States and elsewhere as a 3% ointment or cream and a powder.

General Manufacturing Information · 2 件

8-Quinolinol, 5-chloro-7-iodo-: ACTIVE

Sterilizable substitute for iodoform.

応用分野 · 3 件

解説C9H5NOClI(305.52).5-クロロ-7-ヨード-8-キノリノール(5-chloro-7-iodo-8-quinolinol)ともいう.クリオキノールは,淡黄白色~淡黄褐色の軽質の粉末.わずかに特異な臭いを呈する.無味.融点約175 ℃(分解).熱氷酢酸,ジメチルホルムアミドに易溶,水,エタノールに不溶.光によって徐々に変化する.各種細菌や赤痢アメーバなどの原虫による疾患に有効な内服可能の殺菌剤。腸管からの吸収が少なく、消化管内の殺菌や腸内異常発酵の抑制に有効なため、細菌性の下痢症の治療に腸内殺菌剤、止瀉(ししゃ)剤(下痢どめ)として繁用されたが、1970年(昭和45)スモンの一原因としてその副作用が重大問題となり、医薬品としての製造販売が禁止された。森北出版「化学辞典(第2版)

使用Clioquinol is used as an anti-infective agent; antiamoebic agent; intravaginal trichomonacide; used to impregnate cotton bandages for antibacterial purposes; in animals as an intestinal anti-infective agent.

一般的な説明Cream-colored to brownish-yellow powder. Practically odorless. Decomposes at 178-179°C. Used as a topical anti-infective.

調製方法

純化方法It crystallises from AcOH or xylene and dry it at 70o in vacuo.[Beilstein 21 III/IV 1190.]

上流・下流製品情報

上流原料

水酸化物

下流製品

5,7-ジクロロ-8-ヒドロキシキノリン
補足説明 · 1 件

定義ChEBI: A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has al o been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.